Examkin

Soru

Zorluk: ZorGynecologic Infections

A 24-year-old woman comes to the clinic for a follow-up visit regarding persistent vaginal discharge and spotting after intercourse. Three weeks ago, she presented with similar symptoms and was diagnosed with cervicitis. A nucleic acid amplification test (NAAT) at that time was positive for *Chlamydia trachomatis* and negative for *Neisseria gonorrhoeae*. She was prescribed a 7-day course of oral doxycycline, which she completed. Her new male sexual partner was also treated, and they abstained from sexual activity for 10 days. Today, her vital signs are within normal limits. Pelvic examination reveals an erythematous, friable cervix with mucopurulent discharge. No cervical motion tenderness or adnexal tenderness is appreciated. A repeat NAAT for *C. trachomatis* and *N. gonorrhoeae* is negative. Wet mount microscopy shows numerous polymorphonuclear leukocytes but no clue cells, trichomonads, or pseudohyphae. Which of the following is the most appropriate next step in management?

  1. Nucleic acid amplification testing for Mycoplasma genitaliumCevap
  2. B
    Empiric administration of single-dose oral azithromycin
  3. C
    Colposcopy with directed cervical biopsy
  4. D
    Reassurance and routine follow-up
  5. E
    Prescription of single-dose oral fluconazole

Cevap

Nucleic acid amplification testing for Mycoplasma genitalium
The correct answer is to perform nucleic acid amplification testing (NAAT) for Mycoplasma genitalium. This patient has persistent cervicitis, evidenced by mucopurulent discharge and cervical friability, despite documented compliance with a standard doxycycline regimen for Chlamydia trachomatis. Partner treatment and a negative repeat NAAT make reinfection highly unlikely. In cases of persistent or recurrent cervicitis where Neisseria gonorrhoeae, C. trachomatis, and Trichomonas vaginalis have been ruled out, M. genitalium is the most common causative organism. The Centers for Disease Control and Prevention (CDC) guidelines recommend testing for M. genitalium in all patients with persistent cervicitis or pelvic inflammatory disease (PID). Because M. genitalium has high rates of macrolide resistance, diagnosis must be confirmed via NAAT before initiating specific, targeted therapy (often sequential therapy with doxycycline followed by moxifloxacin or a resistance-guided approach).

Adım Adım Çözüm

1
Analyze the patient's initial presentation and treatment.
The patient had confirmed Chlamydia cervicitis and was adequately treated with doxycycline. Her partner was treated, minimizing the risk of reinfection.
Establishing adequate initial treatment helps differentiate treatment failure/reinfection from a new or co-pathogen.
2
Evaluate the current clinical findings and test results.
She has persistent mucopurulent cervicitis. Repeat GC/CT NAAT is negative (ruling out reinfection). Wet mount shows only leukocytes (ruling out Trichomonas and candidiasis).
Negative repeat tests confirm that the initial Chlamydia infection has cleared and points toward an alternative etiology.
3
Determine the most likely etiology for persistent cervicitis.
Mycoplasma genitalium is the most common cause of persistent or recurrent cervicitis and urethritis after standard treatment for Chlamydia.
Current CDC guidelines mandate specific testing for M. genitalium in this clinical scenario.
4
Select the appropriate diagnostic or therapeutic step.
NAAT for Mycoplasma genitalium is the best next step to guide targeted resistance-guided therapy.
Empiric macrolide therapy (azithromycin) is no longer advised due to high resistance rates; confirming the diagnosis first is required for proper antibiotic stewardship.

Anahtar Kavram

In women with persistent cervicitis despite appropriate therapy for Chlamydia and Gonorrhea, Mycoplasma genitalium is the most likely pathogen and should be confirmed via NAAT.
Tahmini Süre:1m 30s
Bu soruyu puanla

Konular

Gynecologic Infections

Bu konudan daha fazla soru